Utah Medical Products, Inc. (UTMD)
NASDAQ: UTMD · Real-Time Price · USD
56.39
-0.82 (-1.43%)
At close: Jul 11, 2025, 4:00 PM
56.43
+0.04 (0.07%)
After-hours: Jul 11, 2025, 4:04 PM EDT
Utah Medical Products Market Cap
Utah Medical Products has a market cap or net worth of $183.30 million as of July 11, 2025. Its market cap has decreased by -22.53% in one year.
Market Cap
183.30M
Enterprise Value
100.24M
1-Year Change
-22.53%
Ranking
Category
Stock Price
$56.39
Market Cap Chart
Since March 8, 1999, Utah Medical Products's market cap has increased from $49.30M to $183.30M, an increase of 271.80%. That is a compound annual growth rate of 5.11%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jul 11, 2025 | 183.30M | -12.09% |
| Dec 31, 2024 | 208.50M | -31.80% |
| Dec 29, 2023 | 305.70M | -16.18% |
| Dec 30, 2022 | 364.70M | -0.11% |
| Dec 31, 2021 | 365.10M | 18.96% |
| Dec 31, 2020 | 306.90M | -23.56% |
| Dec 31, 2019 | 401.50M | 29.43% |
| Dec 31, 2018 | 310.20M | 2.41% |
| Dec 29, 2017 | 302.90M | 10.71% |
| Dec 30, 2016 | 273.60M | 24.65% |
| Dec 31, 2015 | 219.50M | -2.36% |
| Dec 31, 2014 | 224.80M | 5.15% |
| Dec 31, 2013 | 213.80M | 60.99% |
| Dec 31, 2012 | 132.80M | 35.10% |
| Dec 30, 2011 | 98.30M | 1.13% |
| Dec 31, 2010 | 97.20M | -8.13% |
| Dec 31, 2009 | 105.80M | 25.95% |
| Dec 31, 2008 | 84.00M | -27.84% |
| Dec 31, 2007 | 116.40M | -10.67% |
| Dec 29, 2006 | 130.30M | 5.59% |
| Dec 30, 2005 | 123.40M | 33.55% |
| Dec 31, 2004 | 92.40M | -23.38% |
| Dec 31, 2003 | 120.60M | 28.30% |
| Dec 31, 2002 | 94.00M | 37.43% |
| Dec 31, 2001 | 68.40M | 81.43% |
View and export this data all the way back to 1999.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 711.91B |
| Johnson & Johnson | 377.51B |
| AbbVie | 339.94B |
| Novo Nordisk | 305.41B |
| UnitedHealth Group | 275.86B |
| Novartis AG | 236.71B |
| Abbott Laboratories | 229.69B |
| AstraZeneca | 218.74B |